Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627844 | 1.00 | NOTUM (0.40) | NOTUMMEN1LMNATHRBBLM | |
| SCHEMBL5248954 | 0.89 | GRIA1 (0.41) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL21443855 | 0.86 | GRIA1 (0.36) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL5542226 | 0.81 | NOTUM (0.40) | NOTUMPARP1PARP10PARP11 | |
| SCHEMBL17498074 | 0.81 | NOTUM (0.40) | NOTUMPARP1PARP10PARP11ALDH1A1 | |
| SCHEMBL8364082 | 0.79 | NOTUM (0.43) | NOTUMMEN1LMNAKMT2APARP1 | |
| SCHEMBL15330821 | 0.77 | PARP1 (0.60) | PARP1PARP10PARP11 | |
| SCHEMBL4206469 | 0.75 | BCHE (0.39) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL14619694 | 0.75 | RXRA (0.46) | — | |
| SCHEMBL97178 | 0.74 | NPC1 (0.47) | MEN1LMNATHRBBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-10807951-B2 | mTORC1 modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020017587-A1 | PYRIDAZINONE DERIVATIVE | 大日本住友製薬株式会社 | 2020-01-23 | — | — | WO | disclosed |
| US-20190112268-A1 | mTORC1 MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-18 | — | — | US | disclosed |
| US-7230118-B2 | Process for the preparation of ropinirole | URQUIMA S.A. (ES) | 2007-06-12 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070032540-A1 | Process for the preparation of ropinirole | URGUIMA S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SCN1A, SCN1B, SCN3A | NOTUM 3603/4885MEN1 901/4885LMNA 154/4885 |
| US-20070032540-A1 | Process for the preparation of ropinirole | PRLHR, COMT, DRD4 | NOTUM 2244/4885MEN1 3310/4885LMNA 4265/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | NOTUM 3419/4885MEN1 2074/4885LMNA 2124/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | NOTUM 1736/4885MEN1 2063/4885LMNA 278/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | NOTUM 2309/4885MEN1 2678/4885LMNA 2421/4885 |
| US-20190112268-A1 | mTORC1 MODULATORS | MTOR, RPTOR, RICTOR | NOTUM 3808/4885MEN1 1005/4885LMNA 4070/4885 |
| US-10807951-B2 | mTORC1 modulators | MTOR, RPTOR, RICTOR | NOTUM 3808/4885MEN1 1005/4885LMNA 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.